SGLT2 inhibitors, when administered to patients with Type 2 diabetes, result in an improved glycemic control, which is attributable to the agents' glucuretic effect, in addition to weight loss and reduced blood pressure. Dapagliflozin (Forxiga®), a new SGLT2 inhibitor, has been available in Belgium since October 2016. This article sought to review recent scientific data from controlled trials assessing dapagliflozin versus placebo or active comparators in Type 2 diabetic patients. Forxiga® was found to be associated with a reduction in HbA1c, along with weight loss and decreased blood pressure levels. The reported adverse events included mild urinary and genital infections. In Belgium, Forxiga® is approved for use in a dual- or triple-therapy regimen, also in combination with basal insulin.
What is already known about the topic?
SGLT2 inhibitors are a new class of drugs for the treatment of type 2 diabetes.
What does this article bring up for us?
Based on recent scientific data, this article clearly shows that dapagliflozin (Forxiga®), either alone or in combination with other antidiabetic agents, was associated with clear-cut benefits in terms of glycemic control, weight loss, and blood pressure levels.
Key Words
Type 2 diabetes, treatment, dapagliflozin, HbA1c, weight, blood pressure, heart, kidney